Revisiting the biological roles of PAI2 (SERPINB2) in cancer (Q37189305)

18 August 2017

1 reference

title

Revisiting the biological roles of PAI2 (SERPINB2) in cancer (English)

1 reference

18 August 2017

David R Croucher

1

0 references

Darren N Saunders

object named as

Darren N Saunders

series ordinal

2

0 references

Marie Ranson

object named as

Marie Ranson

series ordinal

4

0 references

Sergei Lobov

series ordinal

3

object named as

Sergei Lobov

1 reference

PubMed ID

18548086

18 August 2017

language of work or name

English

0 references

publication date

12 June 2008

1 reference

18 August 2017

Nature Reviews Cancer

1 reference

18 August 2017

8

1 reference

18 August 2017

7

1 reference

18 August 2017

535-545

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2400

18 August 2017

0 references

cites work

Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma

1 reference

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas

21 January 2018

1 reference

LRP: a multifunctional scavenger and signaling receptor

21 January 2018

1 reference

Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner

21 January 2018

1 reference

Plasminogen activator inhibitor type 2 in breast cancer.

21 January 2018

1 reference

Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma

21 January 2018

1 reference

Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Plasminogen activation and cancer

31 March 2020

1 reference

The urokinase plasminogen activator system: role in malignancy

31 March 2020

1 reference

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

31 March 2020

1 reference

The Urokinase/PAI-2 Complex

31 March 2020

1 reference

A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells

31 March 2020

1 reference

Pivotal role of plasminogen-activator inhibitor 1 in vascular disease

31 March 2020

1 reference

Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease

31 March 2020

1 reference

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling

31 March 2020

1 reference

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

31 March 2020

1 reference

Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment.

31 March 2020

1 reference

The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility

31 March 2020

1 reference

Regulation of cell adhesion by PAI-1.

31 March 2020

1 reference

Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth

31 March 2020

1 reference

The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.

31 March 2020

1 reference

Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells

31 March 2020

1 reference

Plasminogen activator-specific inhibitors produced by human monocytes/macrophages

31 March 2020

1 reference

Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy

31 March 2020

1 reference

The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival

31 March 2020

1 reference

Deficiency of plasminogen activator inhibitor-2 impairs nutritionally induced murine adipose tissue development

31 March 2020

1 reference

The plasminogen activating system in periodontal health and disease

31 March 2020

1 reference

Plasminogen activators and their inhibitors in human saliva and salivary gland tissue

31 March 2020

1 reference

Human intraperitoneal fibrinolytic response to elective surgery

31 March 2020

1 reference

Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions

31 March 2020

1 reference

Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-golgi-independent pathway.

31 March 2020

1 reference

The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

31 March 2020

1 reference

Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2

31 March 2020

1 reference

Molecular characterization of plasminogen activators in human gingival crevicular fluid

31 March 2020

1 reference

Tissue-specific expression of the relaxed conformation of plasminogen activator inhibitor-2 and low-density lipoprotein receptor-related protein in human term gestational tissues

31 March 2020

1 reference

Structure of a serpin-protease complex shows inhibition by deformation

31 March 2020

1 reference

Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif

31 March 2020

1 reference

Interaction of plasminogen activator inhibitor-2 and proteasome subunit, beta type 1.

31 March 2020

1 reference

Interaction between plasminogen activator inhibitor type-2 and pre-mRNA processing factor 8.

31 March 2020

1 reference

The exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain

31 March 2020

1 reference

Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

31 March 2020

1 reference

Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1

31 March 2020

1 reference

Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells

31 March 2020

1 reference

NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta

31 March 2020

1 reference

Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor α-induced Apoptosis

31 March 2020

1 reference

Thrombin inhibits apoptosis of monocytes and plasminogen activator inhibitor 2 (PAI-2) is not responsible for this inhibition

31 March 2020

1 reference

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

31 March 2020

1 reference

Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

31 March 2020

1 reference

Molecular gymnastics: serpin structure, folding and misfolding

31 March 2020

1 reference

Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms

31 March 2020

1 reference

Functional evaluation of plasmin formation in primary breast cancer

31 March 2020

1 reference

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers

31 March 2020

1 reference

Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.

31 March 2020

1 reference

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model

31 March 2020

1 reference

In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells

31 March 2020

1 reference

Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma

31 March 2020

1 reference

Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.

31 March 2020

1 reference

Dissemination risk index based on plasminogen activator system components in primary breast cancer

31 March 2020

1 reference

Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues

31 March 2020

1 reference

Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues

31 March 2020

1 reference

31 March 2020

1 reference

The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes

31 March 2020

1 reference

Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein

31 March 2020

1 reference

The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro

31 March 2020

1 reference

Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves

31 March 2020

1 reference

Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis

31 March 2020

1 reference

Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein

31 March 2020

1 reference

Binding site structure of one LRP-RAP complex: implications for a common ligand-receptor binding motif

31 March 2020

1 reference

EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma

31 March 2020

1 reference

Urokinase receptor: a molecular organizer in cellular communication.

31 March 2020

1 reference

The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.

31 March 2020

1 reference

Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction

31 March 2020

1 reference

Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells

31 March 2020

1 reference

Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598

31 March 2020

1 reference

Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc compl

31 March 2020

1 reference

The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells.

31 March 2020

1 reference

Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction

31 March 2020

1 reference

Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells

31 March 2020

1 reference

Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.

31 March 2020

1 reference

Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders

31 March 2020

1 reference

Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility

31 March 2020

1 reference

Diverse roles for the LDL receptor family

31 March 2020

1 reference

Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.

31 March 2020

1 reference

The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.

31 March 2020

1 reference

Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation

31 March 2020

1 reference

Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice

31 March 2020

1 reference

Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors

31 March 2020

1 reference

Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing

31 March 2020

1 reference

Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2.

31 March 2020

1 reference

Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.

31 March 2020

1 reference

Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression.

31 March 2020

1 reference

Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human prostate cancer cells

31 March 2020

1 reference

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination

31 March 2020

1 reference

Breast cancer metastasis: markers and models

31 March 2020

1 reference

The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer

31 March 2020

1 reference

Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size

31 March 2020

1 reference

Prognostic value of the plasminogen activation system in patients with gastric carcinoma

31 March 2020

1 reference

Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer

31 March 2020

1 reference

Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma

31 March 2020

1 reference

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease

31 March 2020

1 reference

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group

31 March 2020

1 reference

Plasminogen activator system in human breast cancer

31 March 2020

1 reference

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity

31 March 2020

1 reference

Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression

31 March 2020

1 reference

The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression

31 March 2020

1 reference

Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer

31 March 2020

1 reference

Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1

31 March 2020

1 reference

Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

31 March 2020

1 reference

Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis

31 March 2020

1 reference

Components of the plasminogen activation system in uveal melanoma—a clinico-pathological study

31 March 2020

1 reference

High tPA-expression in primary melanoma of the limb correlates with good prognosis

31 March 2020

1 reference

Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system

31 March 2020

1 reference

High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.

31 March 2020

1 reference

Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients

31 March 2020

1 reference

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

31 March 2020

1 reference

High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.

31 March 2020

1 reference

31 March 2020

Fibroblasts in cancer

1 reference

The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature

31 March 2020

1 reference

An overview of the serpin superfamily

31 March 2020

1 reference

Plasminogen binding and cancer: promises and pitfalls

31 March 2020

1 reference

Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor

31 March 2020

1 reference

The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

31 March 2020

1 reference

Control of matrix metalloproteinase catalytic activity

31 March 2020

1 reference

Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines

31 March 2020

1 reference

Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability

31 March 2020

1 reference

Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.

31 March 2020

1 reference

Structure and function of the plasminogen/plasmin system

31 March 2020

1 reference

Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1

31 March 2020

1 reference

Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop

31 March 2020

1 reference

Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC2400

1 reference

18 August 2017

1 reference

PubMed ID

18548086